Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bide Pharmatech Co's Total Assets for the quarter that ended in Mar. 2026 was ¥2,542 Mil.
Warning Sign:
If a company builds assets at 27.5% a year, faster than its revenue growth rate of 16.6% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Bide Pharmatech Co's average Total Assets Growth Rate was -29.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 20.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 27.50% per year.
During the past 8 years, Bide Pharmatech Co's highest 3-Year average Total Assets Growth Rate was 73.30%. The lowest was 20.20%. And the median was 42.10%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Bide Pharmatech Co's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Bide Pharmatech Co Total Assets Related Terms
Bide Pharmatech Co Total Assets Historical Data
* Premium members only.
The historical data trend for Bide Pharmatech Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Bide Pharmatech Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bide Pharmatech Co (SHSE:688073) has a Total Assets of ¥2,542 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Bide Pharmatech Co and its competitors.
Is Bide Pharmatech Co's Total Assets too high?
Bide Pharmatech Co's current Total Assets is ¥2,542 Mil. Overall, Bide Pharmatech Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bide Pharmatech Co's Total Assets compare to ZTS?
Bide Pharmatech Co's Total Assets of ¥2,542 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Bide Pharmatech Co and its competitors. Bide Pharmatech Co's current Total Assets is ¥2,542 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bide Pharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, Bide Pharmatech Co (SHSE:688073) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥67.40, compared to a current price of ¥50.65 — trading 24.9% below its estimated fair value. The current Total Assets is ¥2,542 Mil. Bide Pharmatech Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Bide Pharmatech Co (SHSE:688073), the current Total Assets is ¥2,542 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bide Pharmatech Co (SHSE:688073) Overvalued in 2026?
Based on GuruFocus' analysis, Bide Pharmatech Co stock appears to be undervalued.
The current stock price of ¥50.65 is trading 24.9% below its estimated GF Value™ of ¥67.40.
GuruFocus considers Bide Pharmatech Co to be Modestly Undervalued.
Key valuation signals for SHSE:688073:
Total Assets: ¥2,542 Mil
GF Value™: ¥67.40 vs. price of ¥50.65 (24.9% below fair value)
No single metric tells the full story. See the SHSE:688073 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688073 has been successfully added to your 
